NEW YORK (GenomeWeb News) – Curie-Cancer today announced two three-year partnerships between Institute Curie and French biotech firm Meiogenix to further develop that firm's meiotic recombination technology.

Under the terms of the deals, the technology called SpiX, short for Spo11-based technology, will be used in yeast and mice "to exploit the unexplored natural biodiversity of organisms."

Financial and other terms of the deals were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.